Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hep B and HPV Cancer Prevention and Mental Health in Zimbabwe
NCT06786429Phase 4Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Dec 2032
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
01
Overview
Phase 4, open-label trial of recombinant human papillomavirus 9-valent vaccine and Hepatitis B vaccine in human papillomavirus infection, hepatitis B (HBV), Cervical Cancer (CC) and 1 more (2 arms). Primary endpoints: Human Papilloma Virus infection at 10 years, Hepatitis B immunity at 12 months and 2 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccineHepatitis B vaccine
03
Conditions
human papillomavirus infectionhepatitis B (HBV)Cervical Cancer (CC)liver cancer
Beyond the preview
Go deeper on NCT06786429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786429.